<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; import</title>
	<atom:link href="http://www.tapanray.in/tag/import/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Improving Drug Quality in India &#8211; A Bizarre Intent</title>
		<link>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-improving-drug-quality-in-india-a-bizarre-intent</link>
		<comments>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/#comments</comments>
		<pubDate>Sun, 28 Jan 2018 23:43:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Inspectors]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Misplaced]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8778</guid>
		<description><![CDATA[On January 16, 2017, quoting a Government source, a media report revealed, “India&#8217;s drug regulator is looking to inspect US pharmaceutical facilities, making critical medicines so that only high-quality products are imported from them.” This intent follows a similar decision &#8230; <a href="http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Managing Pharma Investors’ Expectations When The Chips Are Down</title>
		<link>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-pharma-investors-expectations-when-the-chips-are-down</link>
		<comments>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/#comments</comments>
		<pubDate>Sun, 18 Jun 2017 23:34:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[activist]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chips]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Investors]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8282</guid>
		<description><![CDATA[Triggered by several critical factors, over a relatively short period of time, a downward spiral is visible with most Indian Pharma stocks, with a significant erosion in market capitalization of many large players in the country. A set of important &#8230; <a href="http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Relevance of Content Marketing In Pharma</title>
		<link>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-relevance-of-content-marketing-in-pharma</link>
		<comments>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/#comments</comments>
		<pubDate>Sun, 11 Jun 2017 23:49:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UDFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8268</guid>
		<description><![CDATA[“Nearly half of pharma industry may come under price control” – was the headline of a media report of June 7, 2017. Although, National Pharmaceutical Pricing Authority (NPPA) has apparently denied any such move, the fact is that the number &#8230; <a href="http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Even Smaller Countries Now Question Indian Drug Quality Standard</title>
		<link>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=even-smaller-countries-now-question-indian-drug-quality-standard</link>
		<comments>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/#comments</comments>
		<pubDate>Sun, 04 Dec 2016 23:42:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[smaller]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vietnam]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8001</guid>
		<description><![CDATA[India has over 135 US-FDA approved pharmaceutical manufacturing units, at present. This number is very significant ranking second behind the United States, and was driving the growth of generic drug exports in the top pharma market of the world. Riding &#8230; <a href="http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Happens To Pharma’s Incredible Ride On The ‘Gravy Train’?</title>
		<link>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-happens-to-pharmas-incredible-ride-on-the-gravy-train</link>
		<comments>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/#comments</comments>
		<pubDate>Sun, 25 Sep 2016 23:42:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[gravy]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[incredible]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ride]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[train]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7828</guid>
		<description><![CDATA[India continues to be one of the fastest growing pharmaceutical market of the world with its over 40 percent of the total pharmaceutical produce is exported around the world. Over half of the total exports constitute of formulations, and the &#8230; <a href="http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s China Dependence On API: A Time To Think ‘Outside The Box’</title>
		<link>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-china-dependence-on-api-a-time-to-think-outside-the-box</link>
		<comments>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/#comments</comments>
		<pubDate>Mon, 21 Sep 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[Advisor]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[out of box]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[year of API]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7086</guid>
		<description><![CDATA[The Department of Pharmaceuticals (DoP) has declared the Year 2015 as the Year of ‘Active Pharmaceutical Ingredient (API)’. Following it up on February 25, 2015, the Union Minister of Chemicals &#38; Fertilizers Ananth Kumar assured the Pharmaceutical Industry that appropriate &#8230; <a href="http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Booming Sales Of Unapproved Drugs: Do We Need “Safe In India” Campaign For Medicines?</title>
		<link>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines</link>
		<comments>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/#comments</comments>
		<pubDate>Mon, 18 May 2015 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Abraham]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[booming]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[Lincoln]]></category>
		<category><![CDATA[may]]></category>
		<category><![CDATA[medicines. PLOS]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Peer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reviewed]]></category>
		<category><![CDATA[Safe in India]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Statement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unapproved]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6622</guid>
		<description><![CDATA[“To sin by silence when they should protest makes cowards of men”                      - Abraham Lincoln Not just the Federal Drug Administration of the United States (USFDA), global concerns are being expressed &#8230; <a href="http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
